Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer

Abstract Recurrent gene mutations and fusions in cancer patients are likely to be associated with cancer progression or recurrence by Vogelstein et al. (Science (80-) 340, 1546–1558 (2013)). In this study, we investigated gene mutations and fusions that recurrently occurred in early-stage cancer pat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Su Han Cho, Shinkyo Yoon, Dae Ho Lee, Sang-We Kim, Kwoneel Kim
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5ab5642c5e294704bbfa5c03faf4b75f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5ab5642c5e294704bbfa5c03faf4b75f
record_format	dspace
spelling	oai:doaj.org-article:5ab5642c5e294704bbfa5c03faf4b75f2021-12-02T18:51:08ZRecurrence-associated gene signature in patients with stage I non-small-cell lung cancer10.1038/s41598-021-99197-w2045-2322https://doaj.org/article/5ab5642c5e294704bbfa5c03faf4b75f2021-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-99197-whttps://doaj.org/toc/2045-2322Abstract Recurrent gene mutations and fusions in cancer patients are likely to be associated with cancer progression or recurrence by Vogelstein et al. (Science (80-) 340, 1546–1558 (2013)). In this study, we investigated gene mutations and fusions that recurrently occurred in early-stage cancer patients with stage I non-small-cell cancer (NSCLC). Targeted exome sequencing was performed to profile the variants and confirmed their fidelity at the gene and pathway levels through comparison with data for stage I lung cancer patients, which was obtained from The Cancer Genome Atlas (TCGA). Next, we identified prognostic gene mutations (ATR, ERBB3, KDR, and MUC6), fusions (GOPC-ROS1 and NTRK1-SH2D2A), and VEGF signaling pathway associated with cancer recurrence. To infer the functional implication of the recurrent variants in early-stage cancers, the extent of their selection pattern was investigated, and they were shown to be under positive selection, implying a selective advantage for cancer progression. Specifically, high selection scores were observed in the variants with significantly high risks for recurrence. Taken together, the results of this study enabled us to identify recurrent gene mutations and fusions in a stage I NSCLC cohort and to demonstrate positive selection, which had implications regarding cancer recurrence.Su Han ChoShinkyo YoonDae Ho LeeSang-We KimKwoneel KimNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Su Han Cho Shinkyo Yoon Dae Ho Lee Sang-We Kim Kwoneel Kim Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer
description	Abstract Recurrent gene mutations and fusions in cancer patients are likely to be associated with cancer progression or recurrence by Vogelstein et al. (Science (80-) 340, 1546–1558 (2013)). In this study, we investigated gene mutations and fusions that recurrently occurred in early-stage cancer patients with stage I non-small-cell cancer (NSCLC). Targeted exome sequencing was performed to profile the variants and confirmed their fidelity at the gene and pathway levels through comparison with data for stage I lung cancer patients, which was obtained from The Cancer Genome Atlas (TCGA). Next, we identified prognostic gene mutations (ATR, ERBB3, KDR, and MUC6), fusions (GOPC-ROS1 and NTRK1-SH2D2A), and VEGF signaling pathway associated with cancer recurrence. To infer the functional implication of the recurrent variants in early-stage cancers, the extent of their selection pattern was investigated, and they were shown to be under positive selection, implying a selective advantage for cancer progression. Specifically, high selection scores were observed in the variants with significantly high risks for recurrence. Taken together, the results of this study enabled us to identify recurrent gene mutations and fusions in a stage I NSCLC cohort and to demonstrate positive selection, which had implications regarding cancer recurrence.
format	article
author	Su Han Cho Shinkyo Yoon Dae Ho Lee Sang-We Kim Kwoneel Kim
author_facet	Su Han Cho Shinkyo Yoon Dae Ho Lee Sang-We Kim Kwoneel Kim
author_sort	Su Han Cho
title	Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer
title_short	Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer
title_full	Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer
title_fullStr	Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer
title_full_unstemmed	Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer
title_sort	recurrence-associated gene signature in patients with stage i non-small-cell lung cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5ab5642c5e294704bbfa5c03faf4b75f
work_keys_str_mv	AT suhancho recurrenceassociatedgenesignatureinpatientswithstageinonsmallcelllungcancer AT shinkyoyoon recurrenceassociatedgenesignatureinpatientswithstageinonsmallcelllungcancer AT daeholee recurrenceassociatedgenesignatureinpatientswithstageinonsmallcelllungcancer AT sangwekim recurrenceassociatedgenesignatureinpatientswithstageinonsmallcelllungcancer AT kwoneelkim recurrenceassociatedgenesignatureinpatientswithstageinonsmallcelllungcancer
_version_	1718377447811973120

Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer

Ejemplares similares